Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31621100 | 1.00 | IDH1 (0.43) | IDH1BTKTGFBR1EGFRNFE2L2 | |
| SCHEMBL1984412 | 0.81 | IDH1 (0.44) | IDH1BTKTGFBR1NFE2L2KDM4E | |
| SCHEMBL18901393 | 0.79 | IDH1 (0.43) | IDH1BTKTGFBR1NFE2L2KDM4E | |
| SCHEMBL28873288 | 0.79 | IDH1 (0.43) | IDH1BTKTGFBR1EGFRNFE2L2 | |
| SCHEMBL29432664 | 0.79 | IDH1 (0.47) | IDH1BTKTGFBR1NFE2L2ALDH1A1 | |
| SCHEMBL3081313 | 0.79 | IDH1 (0.47) | IDH1BTKTGFBR1NFE2L2KDM4E | |
| SCHEMBL506568 | 0.79 | IDH1 (0.47) | IDH1BTKTGFBR1NFE2L2ALDH1A1 | |
| SCHEMBL14861403 | 0.79 | MCHR1 (0.33) | EGFRALDH1A1 | |
| SCHEMBL1476989 | 0.79 | TRPV3 (0.40) | EGFR | |
| SCHEMBL160602 | 0.77 | BTK (0.47) | BTKKDM4EALDH1A1HPGDALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120158618-A | Method for recovering copper ions from semiconductor copper process waste liquid | 武汉盟芯半导体有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-120158618-B | Method for recovering copper ions from semiconductor copper process waste liquid | 武汉盟芯半导体有限公司 | 2025-10-17 | — | — | CN | disclosed |
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-120158618-A | Method for recovering copper ions from semiconductor copper process waste liquid | 武汉盟芯半导体有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-120158618-A | Method for recovering copper ions from semiconductor copper process waste liquid | 武汉盟芯半导体有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118119609-A | Imidazole derivatives and their use as antibiotics | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4370514-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
| EP-2066640-A2 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | N.V. Organon (NL) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008033757-A2 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-13 | — | — | US | disclosed |
| EP-0429565-B1 | GRAFT COPOLYMERS AND LUBRICANTS CONTAINING SUCH AS DISPERSANT-VISCOSITY IMPROVERS | LUBRIZOL CORP (US) | 1996-08-14 | — | — | EP | disclosed |
| US-5298565-A | Polymerization of nitrogen containing monomer onto hydrocarbon backbone, aromatic solvent for hydrogen atom chain transfer | THE LUBRIZOL CORPORATION (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0429565-A1 | GRAFT COPOLYMERS AND LUBRICANTS CONTAINING SUCH AS DISPERSANT-VISCOSITY IMPROVERS. | LUBRIZOL CORP (US) | 1991-06-05 | — | — | EP | disclosed |
| WO-1990012046-A1 | GRAFT COPOLYMERS AND LUBRICANTS CONTAINING SUCH AS DISPERSANT-VISCOSITY IMPROVERS | THE LUBRIZOL CORPORATION (US) | 1990-10-18 | — | — | WO | disclosed |
| US-3954894-A | Organotrilithium polymerization initiators | LITHIUM CORPORATION OF AMERICA (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | IDH1 500/4885BTK 488/4885TGFBR1 1666/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | IDH1 500/4885BTK 488/4885TGFBR1 1666/4885 |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | F12, C1R, MRPL21 | IDH1 500/4885BTK 488/4885TGFBR1 1666/4885 |
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | SULT2A1, ACAT2, HDAC6 | IDH1 135/4885BTK 1274/4885TGFBR1 4682/4885 |
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | IDH1 473/4885BTK 2299/4885TGFBR1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.